Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $46 | $38 | $20 | $8 |
| % Growth | 20.8% | 89.4% | 161% | – |
| Cost of Goods Sold | $6 | $1 | $1 | $0 |
| Gross Profit | $39 | $37 | $19 | $8 |
| % Margin | 86.1% | 96.6% | 95.6% | 100% |
| R&D Expenses | $56 | $62 | $62 | $66 |
| G&A Expenses | $0 | $44 | $41 | $38 |
| SG&A Expenses | $45 | $44 | $41 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4 | $0 | $0 | $1 |
| Operating Expenses | $97 | $106 | $103 | $104 |
| Operating Income | -$57 | -$69 | -$84 | -$96 |
| % Margin | -125.2% | -182.7% | -417.9% | -1,254.8% |
| Other Income/Exp. Net | -$3 | -$2 | -$1 | $2 |
| Pre-Tax Income | -$61 | -$72 | -$85 | -$94 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$61 | -$72 | -$85 | -$94 |
| % Margin | -132.4% | -189.3% | -423.3% | -1,226.2% |
| EPS | -0.7 | -0.83 | -0.99 | -1.1 |
| % Growth | 15.7% | 16.2% | 10% | – |
| EPS Diluted | -0.7 | -0.83 | -0.99 | -1.1 |
| Weighted Avg Shares Out | 87 | 86 | 86 | 86 |
| Weighted Avg Shares Out Dil | 87 | 86 | 86 | 86 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $6 | $7 | $7 |
| Interest Expense | $3 | $8 | $8 | $5 |
| Depreciation & Amortization | $0 | $0 | $9 | $0 |
| EBITDA | -$58 | -$64 | -$84 | -$89 |
| % Margin | -125.8% | -168.6% | -417.9% | -1,163.6% |